Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 14/20 | 0.50 |
| ▸ | FLT4 | P35916 | 5/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | JAK3 | P52333 | 4/20 | 0.46 |
| ▸ | STAT6 | P42226 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14576969 | 0.93 | PTK2 (0.48) | PTK2FLT4KDRJAK3STAT6 | |
| SCHEMBL15514158 | 0.92 | FLT4 (0.53) | PTK2FLT4KDR | |
| SCHEMBL14576563 | 0.92 | PTK2 (0.53) | PTK2FLT4KDRSTAT6 | |
| SCHEMBL15512969 | 0.92 | PTK2 (0.51) | PTK2FLT4KDRJAK3STAT6 | |
| SCHEMBL14577154 | 0.88 | PTK2 (0.52) | PTK2FLT4KDRJAK3STAT6 | |
| SCHEMBL15513769 | 0.88 | FLT4 (0.51) | PTK2FLT4KDRJAK3STAT6 | |
| SCHEMBL15513196 | 0.87 | FLT4 (0.55) | PTK2FLT4KDRJAK3JAK2 | |
| SCHEMBL15513022 | 0.86 | FLT4 (0.49) | PTK2FLT4KDRJAK3STAT6 | |
| SCHEMBL12478142 | 0.85 | PTK2 (0.49) | PTK2FLT4KDRSTAT6 | |
| SCHEMBL12479394 | 0.85 | PTK2 (0.48) | PTK2FLT4KDRJAK3JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2675793-B1 | FAK INHIBITORS | CANCER THERAPEUTICS CRC PTY LTD (AU) | 2018-08-08 | — | — | EP | disclosed |
| US-9421205-B2 | FAK inhibitors | Cancer Therapeutics CRC Pty Ltd. (AU) | 2016-08-23 | — | — | US | disclosed |
| US-20150231135-A1 | FAK INHIBITORS | Cancer Therapeutics CRC Pty Ltd. (AU) | 2015-08-20 | — | — | US | disclosed |
| US-9012461-B2 | FAK inhibitors | CANCER THERAPEUTICS CRC PTY LTD (AU) | 2015-04-21 | — | — | US | disclosed |
| EP-2675793-A1 | FAK INHIBITORS | Cancer Therapeutics Crc Pty Limited (AU) | 2013-12-25 | — | — | EP | disclosed |
| US-20130324532-A1 | FAK INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2013-12-05 | — | — | US | disclosed |
| US-20130017194-A1 | FAK INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2013-01-17 | — | — | US | disclosed |
| WO-2012110773-A1 | FAK INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2012-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130017194-A1 | FAK INHIBITORS | PTK2, CTTN, SRC | PTK2 1/4885FLT4 617/4885KDR 189/4885 |
| US-20130324532-A1 | FAK INHIBITORS | PTK2, CTTN, SRC | PTK2 1/4885FLT4 617/4885KDR 189/4885 |
| US-20150231135-A1 | FAK INHIBITORS | PTK2, CTTN, SRC | PTK2 1/4885FLT4 791/4885KDR 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.